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JOURNAL OF HEPATOLOGYNon-alcoholic fatty liver disease, alcohol intake and psoriasisTo the Editor:
We read the interesting report by Gisondi et al. published in a
recent issue of the Journal of Hepatology [1]. In this study, the
authors found that patients affected by severe psoriasis exhibited
an undiagnosed non-alcoholic fatty liver disease (NALFD) in
almost 50% of cases and suggested that psoriasis might be a
major risk factor for NALFD development.
The study shed light on this important issue, but there are
some concerns regarding selection of patients and the method
used to measure alcohol consumption.
Gisondi et al. state that the following amounts of alcoholic
beverages were considered one drink: ‘‘330 ml beer (containing
5% of alcohol), 150 ml wine (containing 12% of alcohol), and
40 ml strong alcohol (containing 50% of alcohol)”. Calculating
the amount of ethanol (EtOH) of each drink, it appears that the
beer contains about 13.2 g of EtOH, the wine 14.4 g and the
strong alcohol about 16 g. These data indicate that the group of
33 patients consuming 62 drinks had an alcohol intake of
26.4–32.0 g, depending on the type of beverages, whereas the
group of 20 patients consuming 3–4 drinks had an alcohol intake
of 39.6–64.0 g. Literature data have demonstrated that male
patients consuming more than 30 g and female patients consum-
ing more than 20 g of EtOH daily should be excluded from the
cohort when dealing with NAFLD because it is plausible that they
may already have an alcohol-related liver disease [2]. Conse-
quently, the authors should have excluded from their study the
group of patients consuming 3–4 beverages/day and apply differ-
ent cut-offs for males and females to include only patients ﬁtting
the above-mentioned criteria for NAFLD.
Moreover, Gisondi et al. have calculated the prevalence of
NAFLD in non-drinking patients (37%), which is lower compared
to the psoriasis-affected population considered in their study,
which include drinker and non-drinker patients. However, the
prevalence of liver disease should also be calculated in light ofmod-
erate drinkerswith psoriasis (consuming62 drinks and 3–4 drinks,
respectively) in order to analyze the contribution of these groups in
achieving a total NAFLD prevalence of 47% in psoriatic patients.
Co-morbidities in psoriasis have been deeply investigated in
the last years. The relationship between psoriasis and comorbi-
dities is probably related to the underlying chronic inﬂammatoryJournal of Hepatology 20process. In this regard, emerging co-morbidities of psoriasis
include cardiovascular disease and metabolic syndrome, notably
obesity, dyslipidemia, and insulin resistance. Therefore, it is plau-
sible that chronic systemic inﬂammation, as observed in psoria-
sis, may also be responsible for NAFLD [3] and this association
should be considered when dealing with patients affected by pso-
riasis, as reported by Gisondi et al. However, the prevalence of
this association is probably overestimated and we believe that
an accurate evaluation of the daily alcohol intake using the
world-wide established alcoholic unit (corresponding to 8 g of
EtOH) may improve the selection of patients in which NAFLD
prevalence has to be calculated.
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